Reply to: "correspondence about "Efficacy and safety of basiliximab"
Ann Hepatol
.
2022 Mar-Apr;27(2):100679.
doi: 10.1016/j.aohep.2022.100679.
Epub 2022 Jan 29.
Authors
Mohamed Hashim
1
,
Ayman Alsebaey
2
,
Amr Ragab
2
,
Hossam Eldeen Soliman
3
,
Imam Waked
2
Affiliations
1
Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt. Electronic address: msaadhh@hotmail.com.
2
Department of Hepatology, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.
3
Department of Hepatobiliary and Pancreatic Surgery, National Liver Institute, Menoufiya University, Shebin Elkom, Egypt.
PMID:
35101617
DOI:
10.1016/j.aohep.2022.100679
No abstract available
Publication types
Letter
Comment
MeSH terms
Basiliximab
Graft Rejection*
Humans
Immunosuppressive Agents*
Substances
Immunosuppressive Agents
Basiliximab